· B		•			فير.								,							
相11周	FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						D	ATTY. DOCKET NO. A0000426-01-CFP					AL NO. 7 5,918	H CEN	FEB					
PKTEN	SUPPLEM		ΓAL ΓΕΜ								SU	RE		PPLICAN'	Γ intel Barvian, et a	ıl.			댶	1 4
		(U	se se	veral	shee	ts if	neces	ssary	/)					LING DA' 'ebruary			GROU 1623	JP	וסטטובשטט	2003
										1	U.	S. P.	ΑT	ENT I	OCUMEN'	TS			7300	
	EXAMINER INITIAL			DO	CUI	ME	NT I	NU	мв			1	TE		NAME		CLASS	SUBCLASS		DATE
	_			_	Ļ				_	_	1	-				-				
		П	+	\dagger		Н		+	+		_									
																=				
	-																			
		Ш	_	\perp		Ц	\perp			_	1	<u> </u>								
		Ц		1			\perp													
									F	OI	RF	iiGi	ΝP	ATEN	T DOCUM	ENTS				
				DC	CU	ME	NT	NU		ER		DA			COUNTRY		CLAS	SS SUBCLA	SS TRANSI	LATION
		_	ļ	r			_	,	_		_	<u> </u>			-		ļ		YES	NO
	-40	-	W	0	9	9	0	5	3	+-	9	+					 			X
	- \$	-	W	۲	5	1	9	3	2	6	8	+		JAPAN			 			X
1	7					Ė	_		Ĺ	Ť	Ť	105.0	0.75	37117111		-				
`						Г		Г	Π	Г	Г								+	
											T		•							
								•	_			•	·	<u> </u>						
	0	TH	IE.	<u>R J</u>											thor, Title, 1					
	120						tros	cop	у а	nd (a Novel, Potent, a lar Design", Journa					g NMR
				Ì											class of small-mol					
	Ì				ľ	om	bina	tor	ial l	ibra	ries	which	ı fun	ction by ir	hibiting the binding the hinding themical Society 2	ng and loo	alizatio	n of proteinas	e MMP2 to i	integrin.

7	Chen JM et al., "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", Journal of the American Chemical Society 2000; 122:9648-9654
	Boger, DL et al., "Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin. alpha. V. beta. 3, Journal of the American Chemical Society 2001; 123:1280-1288
	Silletti, S. et al, "Disruption of matrix metalloproteinase 2 binding to integrin alpha. v. beta. 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo", Proceeding of the National Academy of Sciences of the United States of America 2001; 98(1)119-124
	Milton J. et al, "Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2", Bioorganic & Medicinal Chemistry Letters, Oxford, GB 1998; 8:2623-2628
EXAMINER	Dayl VIA DATE CONSIDERED 60/1/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	ute for form 1449A/PTC	•	PATENT 8		nplete if Kn wn	-1
INIT	ODMATION	DICA	01 00UDE	Application Number	10/075,918	0
	ORMATION			Filing Date	February 13, 2002	工
STA	TEMENT B	Y AF	PPLICANT	First Named Inventor	Nicole Chantel Barvian, et	t ak
				Group Art Unit	1623	2
	(use as many shee	ets as r	ecessary)	Examiner Name	Unknown	mi
Sheet	1	of	2	Attorney Docket Number	A0000426-01-CFP	

				U.S. PATENT DOCU	IMENTS		$\overline{\mathcal{O}}$
Examiner Initials*	Cite No.1	U.S. Patent I	Cocument Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	/2900
14		5,948,780		Peterson, Jr., et al	09/07/0199		····
<u> </u>		6,008,243		Bender, et al	12/28/0199		
$\overline{}$			\dashv		_		
			 -		\leftarrow		
į					 		
							
	-				 	· · · · · · · · · · · · · · · · · · ·	

				FORE	GN PATENT DOCUMENTS	S		
Examiner	Cite		Foreign Patent Docum	nent	Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	Т
	No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Ţ
94	•	WO	01/63244 A1		Chen, et al			I
_	_				 			1
				- - -		+		+
				$\Rightarrow \Rightarrow$				十
				\rightarrow				1
\longrightarrow						 		╬
		 		++		 		+

Examiner Signature	Torgh	V AL	Date Considered	1-11/03
U-ignature	//	11 4	00110100100	,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute	e for form 1449B/P	то	PATENT &	Сп	npl t if Known	EC!
		RMATION DISCLOSURE EMENT BY APPLICANT (use as many sheets as necessary) 2 of 2		Application Number	10/075,918	
INFO	RMATIO	N DIS	CLOSURE	Filing Date	February 13, 2002	πi
STA	TEMENT	BY A	PPI ICANT	First Named Inventor	Nicole Chantel Barvian,	et 📶
• • • • • • • • • • • • • • • • • • • •		D .,,		Group Art Unit	1623	
	(use as many	y sheets as	necessary)	Examiner Name	Unknown	
Sheet	2	of	2	Attorney Docket Number	A0000426-01-CFP	600
						123

			<u> </u>
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	8
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
4		MONTANA, John, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitors", Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361	
		CLARK, Ian, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25	
V		CHEN, James, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-9654	
		<u> </u>	1

Signature Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Date

Examiner

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.